U.S. Markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.46-0.94 (-2.33%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close40.40
Open40.11
Bid39.46 x 900
Ask39.50 x 1100
Day's Range38.76 - 40.30
52 Week Range20.15 - 99.95
Volume1,006,355
Avg. Volume2,659,473
Market Cap2.658B
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-1.98
Earnings DateMay 06, 2021 - May 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.57
  • An End to This Rare Syndrome Could Be an Opportunity for Investors
    Motley Fool

    An End to This Rare Syndrome Could Be an Opportunity for Investors

    A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

  • Motley Fool

    Here's the Holy Grail of Gene Editing

    In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the difference between ex vivo gene editing (outside the body) and in vivo editing (within the patient). CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) have mastered ex vivo gene editing, but the strategy is limited to diseases where cells can be manipulated outside the body. Up-and-coming gene editing companies may have a bigger opportunity if they can master the in vivo technique.

  • 3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich
    Motley Fool

    3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich

    You've no doubt heard the investing adage to "buy the dip." But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea. On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run.